Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2020 - 2025)

Insight Molecular Diagnostics' Cash & Equivalents history spans 6 years, with the latest figure at $18.7 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 450.0% year-over-year to $18.7 million; the TTM value through Sep 2025 reached $18.7 million, up 450.0%, while the annual FY2024 figure was $8.6 million, 8.44% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $18.7 million at Insight Molecular Diagnostics, down from $24.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $46.5 million in Q2 2021 and bottomed at $441000.0 in Q3 2023.
  • The 5-year median for Cash & Equivalents is $18.7 million (2025), against an average of $18.8 million.
  • The largest annual shift saw Cash & Equivalents plummeted 98.82% in 2023 before it soared 1646.42% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $32.9 million in 2021, then plummeted by 39.32% to $20.0 million in 2022, then crashed by 52.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then skyrocketed by 116.54% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cash & Equivalents are $18.7 million (Q3 2025), $24.3 million (Q2 2025), and $31.0 million (Q1 2025).